Compass Group PLC Sponsored ADR (CMPGY)
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clouds FDA approval prospects. The Q3 2026 FDA meeting is pivotal; approval could nearly double the stock, while rejection risks 50% dilution and multi-year delays.
Compass Minerals: Why This Turnaround Is Different
Compass Minerals (CMP) is undergoing a structural transformation, prioritizing disciplined capital allocation and operational efficiency over cyclical growth. CMP's portfolio simplification and focus on core salt and plant nutrition segments have improved cash flow, reduced debt, and strengthened financial stability. Despite a 14.9% EV/EBITDA discount to the sector median, CMP's ongoing deleveraging and operational gains are not yet recognized by the market.
Compass Minerals: Why I Think The Market Is Mispricing The Recovery
Compass Minerals International is rated Buy with a fair value range of $31–$36, reflecting 4–21% upside from current levels. Significant deleveraging, net leverage down from 4.6x to 2.7x, and S&P credit upgrade, positions CMP for multiple expansion. Salt cost normalization and Plant Nutrition margin gains are key forward catalysts; Salt's counter-cyclical cash flows enhance CMP's relative appeal.
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-resistant depression, as the company works toward a potential U.S. launch in the first half of 2027.
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
Compass Group: Why This Compounder Giant May Not Outperform The Market In 2026
Compass Group (CMPGY) remains a high-quality compounder, but current valuation leaves limited upside, justifying a 'Hold' rating. CMPGY delivered 9% H1 FY 2026 revenue growth and 12% EBIT growth, outpacing historical rates as international and M&A strategies drive expansion. Organic revenue is guided to ~7% for FY 2026, with EBIT expected to grow 11% and margins benefiting from scale and bolt-on acquisitions.
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
Compass Therapeutics NASDAQ: CMPX Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secondary endpoint.
AG's antitrust probe decimates Compass stock price by nearly 13%
Compass' stock price plummeted Wednesday after news broke that the New York Attorney General's office was investigating the brokerage over antitrust concerns.
Compass Pathways: A Trip Worth Taking Before The FDA Verdict
COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-resistant depression (TRD), with expected FDA approval later this year. COMP360 demonstrated primary endpoint success in Phase 3 trials, with potential for less frequent dosing and improved convenience over Spravato, the current TRD market leader. My fair value estimate for CMPS is $13.63 per share, probability-weighted for FDA approval, with upside to $18.65 if approved and downside to $6.96 if a CRL is issued.
Compass: Profit Can Multiply When Housing Market Recovers
Compass offers exposure to the undervalued housing sector and is now the largest U.S. real estate broker after acquiring Anywhere Real Estate. Despite a 20% YTD decline, COMP is outperforming the flat real estate market with mid/high single-digit sales growth and strong agent retention at 94%. Bundling title and escrow services, especially post-acquisition, is boosting revenue per transaction and expanding the company's addressable market.
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timeline.
Exclusive: Compass Minerals eyes return to lithium market with EnergyX partnership
Compass Minerals plans to jump back into the lithium market by partnering with technology startup EnergyX to extract the battery metal from Utah's Great Salt Lake, a move that comes as prices rise for the critical mineral alongside a broader push to boost U.S. output.
